|
1
|
Brown KD, Zurawski SM, Mosmann TR, et al:
A family of small inducible proteins secreted by leukocytes are
members of a new superfamily that includes leukocyte and
fibroblast-derived inflammatory agents, growth factors, and
indicators of various activation processes. J Immunol. 142:679–687.
1989.
|
|
2
|
Smirnov DV, Smirnova MG, Korobko VG, et
al: Tandem arrangement of human genes for interleukin-4 and
interleukin-13: resemblance in their organization. Gene.
155:277–281. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Terabe M, Park JM and Berzofsky JA: Role
of IL-13 in regulation of anti-tumor immunity and tumor growth.
Cancer Immunol Immunother. 53:79–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Joshi BH, Hogaboam C, Dover P, et al: Role
of interleukin-13 in cancer, pulmonary fibrosis, and other
T(H)2-type diseases. Vitam Horm. 74:479–504. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wynn TA: IL-13 effector functions. Annu
Rev Immunol. 21:425–456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Obiri NI, Debinski W, Leonard WJ, et al:
Receptor for interleukin 13. Interaction with interleukin 4 by a
mechanism that does not involve the common gamma chain shared by
receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem.
270:8797–8804. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aman MJ, Tayebi N, Obiri NI, et al: cDNA
cloning and characterization of the human interleukin 13 receptor
alpha chain. J Biol Chem. 271:29265–29270. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zurawski SM, Vega F Jr, Huyghe B, et al:
Receptors for interleukin-13 and interleukin-4 are complex and
share a novel component that functions in signal transduction. EMBO
J. 12:2663–2670. 1993.PubMed/NCBI
|
|
9
|
Hilton DJ, Zhang JG, Metcalf D, et al:
Cloning and characterization of a binding subunit of the
interleukin 13 receptor that is also a component of the interleukin
4 receptor. Proc Natl Acad Sci USA. 93:497–501. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O’Shea JJ, Gadina M and Schreiber RD:
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.
Cell. 109(Suppl): S121–S131. 2002.PubMed/NCBI
|
|
11
|
Kawakami K, Taguchi J, Murata T, et al:
The interleukin-13 receptor alpha2 chain: an essential component
for binding and internalization but not for interleukin-13-induced
signal transduction through the STAT6 pathway. Blood. 97:2673–2679.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang JG, Hilton DJ, Willson TA, et al:
Identification, purification, and characterization of a soluble
interleukin (IL)-13-binding protein. Evidence that it is distinct
from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J
Biol Chem. 272:9474–9480. 1997. View Article : Google Scholar
|
|
13
|
Andrews AL, Nasir T, Bucchieri F, et al:
IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal
transduction in primary human fibroblasts. J Allergy Clin Immunol.
118:858–865. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiaramonte MG, Mentink-Kane M, Jacobson
BA, et al: Regulation and function of the interleukin 13 receptor
alpha 2 during a T helper cell type 2-dominant immune response. J
Exp Med. 197:687–701. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rahaman SO, Sharma P, Harbor PC, et al:
IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of
IL-4-dependent signal transduction in glioblastoma cells. Cancer
Res. 62:1103–1109. 2002.PubMed/NCBI
|
|
16
|
Fujisawa T, Joshi B, Nakajima A, et al: A
novel role of interleukin-13 receptor alpha2 in pancreatic cancer
invasion and metastasis. Cancer Res. 69:8678–8685. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alberts SR, Sargent DJ, Nair S, et al:
Effect of oxaliplatin, fluorouracil, and leucovorin with or without
cetuximab on survival among patients with resected stage III colon
cancer: a randomized trial. JAMA. 307:1383–1393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tveit KM, Guren T, Glimelius B, et al:
Phase III trial of cetuximab with continuous or intermittent
fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX
alone in first-line treatment of metastatic colorectal cancer: the
NORDIC-VII study. J Clin Oncol. 30:1755–1762. 2012. View Article : Google Scholar
|
|
19
|
Murata T, Noguchi PD and Puri RK: IL-13
induces phosphorylation and activation of JAK2 Janus kinase in
human colon carcinoma cell lines: similarities between IL-4 and
IL-13 signaling. J Immunol. 156:2972–2978. 1996.
|
|
20
|
Mandal D and Levine AD: Elevated
IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis
or colorectal cancer initiates MAPK pathway. Inflamm Bowel Dis.
16:753–764. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fujisawa T, Joshi BH and Puri RK: IL-13
regulates cancer invasion and metastasis through IL-13Rα2 via
ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J
Cancer. 131:344–356. 2012.PubMed/NCBI
|
|
22
|
Wang DJ, Brandsma M, Yin Z, et al: A novel
platform for biologicaly active recombinant human interleukin-13
production. Plant Biotechnol J. 6:504–515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Strober W, Kitani A, Fichtner-Feigl S, et
al: The signaling function of the IL-13Ralpha2 receptor in the
development of gastrointestinal fibrosis and cancer surveillance.
Curr Mol Med. 9:740–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Walczak A, Przybylowska K, Trzcinski R, et
al: Association of −1112 c/t promoter region polymorphism of the
interleukin 13 gene with occurrence of colorectal cancer. Pol
Przegl Chir. 83:27–31. 2011.
|
|
25
|
Gunter MJ, Canzian F, Landi S, et al:
Inflammation-related gene polymorphisms and colorectal adenoma.
Cancer Epidemiol Biomarkers Prev. 15:1126–1131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sinha P, Parker KH, Horn L, et al:
Tumor-induced myeloid-derived supressor cell function is
independent of IFN-γ and IL-4Rα. Eur J Immunol. 42:2052–2059.
2012.
|
|
27
|
Shun MC, Yu W, Gapor A, et al:
Pro-apoptotic mechanisms of action of a novel vitamin E analog
(alpha-TEA) and a naturally occurring form of vitamin E
(delta-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr
Cancer. 48:95–105. 2004. View Article : Google Scholar
|
|
28
|
Koller FL, Hwang DG, Dozier EA, et al:
Epithelial interleukin-4 receptor expression promotes colon tumor
growth. Carcinogenesis. 31:1010–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kanai T, Watanabe M, Hayashi A, et al:
Regulatory effect of interleukin-4 and interleukin-13 on colon
cancer cell adhesion. Br J Cancer. 82:1717–1723. 2000.PubMed/NCBI
|
|
30
|
Honjo Y, Bian Y, Kawakami K, et al:
TGF-beta receptor I conditional knockout mice develop spontaneous
squamous cell carcinoma. Cell Cycle. 6:1360–1366. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mentink-Kane MM and Wynn TA: Opposing
roles for IL-13 and IL-13 receptor alpha 2 in health and disease.
Immunol Rev. 202:191–202. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mitchell J, Dimov V and Townley RG: IL-13
and the IL-13 receptor as therapeutic targets for asthma and
allergic disease. Curr Opin Investig Drugs. 11:527–534.
2010.PubMed/NCBI
|
|
33
|
Nakashima H, Husain SR and Puri RK: IL-13
receptor-directed cancer vaccines and immunotherapy. Immunotherapy.
4:443–451. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hsi LC, Kundu S, Palomo J, et al:
Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous
signaling. Mol Cancer Ther. 10:1149–1160. 2011.
|
|
35
|
Brown CE, Starr R, Aguilar B, et al:
Stem-like tumor-initiating cells isolated from IL-13Rα2 expressing
gliomas are targeted and killed by IL13-zetakine-redirected T
cells. Clin Cancer Res. 18:2199–2209. 2012.PubMed/NCBI
|
|
36
|
Kahlon KS, Brown C, Cooper LJ, et al:
Specific recognition and killing of glioblastoma multiforme by
interleukin 13-zetakine redirected cytolytic T cells. Cancer Res.
64:9160–9166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Balyasnikova IV, Wainwright DA, Solomaha
E, et al: Characterization and immunotherapeutic implications for a
novel antibody targeting interleukin (IL)-13 receptor α2. J Biol
Chem. 287:30215–30227. 2012.PubMed/NCBI
|
|
38
|
Ho-Pun-Cheung A, Assenat E,
Bascoul-Mollevi C, et al: A large-scale candidate gene approach
identifies SNPs in SOD2 and IL13 as predictive markers of response
to preoperative chemoradiation in rectal cancer. Pharmacogenomics
J. 11:437–443. 2011. View Article : Google Scholar : PubMed/NCBI
|
